Brought to you by 
Orexo licenses US rights for Abstral to Galena Biopharma; Galena offloads rights
14 Jan 2021
Executive Summary
Swedish drug delivery firm Orexo AB has granted cancer therapeutics developer Galena Biopharma Inc. exclusive rights to sell its breakthrough cancer pain treatment Abstral (sublingual fentanyl) in the US.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Orexo licenses US rights for Abstral to Galena Biopharma; Galena offloads rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice